The effects of combination of DSF and Galunisertib on the self-renewal ability, the expression of cancer stem cell markers (such as CD133, SOX2, and NANOG), and the ability for differentiation into multiple cell types are necessary. The gene discussed is NANOG; the disease is cancer.